1. Introduction {#sec0005}
===============

Coronavirus disease (COVID-19) is a global public health concern caused by the novel coronavirus SARS-CoV-2 and represents a significant threat to healthcare worldwide. It was first identified in a cluster of patients with pneumonia symptoms in Wuhan city, China, in late 2019. Initially, it was referred to as 2019 nCoV but was later renamed as COVID-19 by the World Health Organization. It is considered to be similar to the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) viruses. The virus can be transferred from human to human through respiratory droplets, contact and fomites. SARS-CoV-2 has two principal strains: 'L type' (70 %) and 'S' (30 %), with the L type being the more aggressive and contagious \[[@bib0005],[@bib0010]\]. Symptoms of COVID-19 vary from asymptomatic, to severe, and include fever, dry cough, pneumonia, malaise, acute respiratory distress syndrome \[[@bib0015]\]. Approximately 80 % of confirmed cases have mild or moderate symptoms, 13.8 % having severe effects and 6.1 % showing critical symptoms, with older adults (≥ 60 years) at higher risk of developing severe disease \[[@bib0020]\]. According to worldometer as of 29 July 2020, SARS-CoV-2 virus has affected over 20 million people worldwide, with more than 732,000 deaths. By the time this paper is published these values will be doubled. These figures are also likely to be significant underestimations, due to lack of testing, reporting, and other factors.

Currently, there are no approved treatments for COVID-19 but prevention strategies such as social distancing, public hygiene and wearing facial masks are the best current approaches to reduce COVID-19. Recent evidence has highlighted that nutritional supplementation could play a supportive role in COVID-19 patients. Administration of higher than recommended daily doses of nutrients such as vitamins D, C, E, Zinc and omega-3 fatty acids might have a beneficial effect, potentially reducing SARS-CoV-2 viral load and length of hospitalization \[[@bib0025], [@bib0030], [@bib0035], [@bib0040]\]. These nutrients are well-known for their antioxidant properties and immunomodulatory effects. Deficiencies in these nutrients can result in immune dysfunction, and increase susceptibility to pathological infection. In fact, dietary insufficiency of vitamins and minerals has been observed in high-risk groups of COVID-19 patients, such as the elderly, increasing the morbidity and risk of mortality \[[@bib0045]\]. It is well known that the elderly are more likely to be nutrient deficient and to have compromised immunity via immuno-senescence, significantly increasing their risk of poor outcomes from COVID-19, and making adequate nutrition doubly important. The role of vitamins D, C, E, Zinc, selenium and omega-3 fatty acids in immunity, their status in patient infected by SARS-CoV-2 and their potential therapeutic role are discussed.

2. Methodology {#sec0010}
==============

The searches carried out in this review were performed as described in [Fig. 1](#fig0005){ref-type="fig"} on July 27, 2020. To identify COVID-19, specific literature, title/abstract searches were conducted in the 'PubMed,\' 'Google Scholar' and 'Science Direct' databases. Search terms included 'COVID-19', 'SARS-CoV-2', 'coronavirus', 'nutrient', 'vitamin', and 'mineral', with filters identifying only studies published since 2020. 211 non-duplicate records were identified and underwent title and abstract screening. A total of 35 relevant studies specifically on COVID-19 and nutrition or diet components were identified. Studies were excluded based on relevance to the topic, with letters to the editor and commentaries also removed. Four published pre-prints are also discussed where relevant and are specifically identified in the manuscript. Included papers with relevant data are summarized in [Table 1](#tbl0005){ref-type="table"} .Fig. 1Summary of search strategy and paper exclusion.Fig. 1Table 1Summary of included studies on COVID-19.Table 1ReferenceDesign/study typeRisk of BiasFinding*Epidemiological background*Guo et al. \[[@bib0005]\]Report/reviewn/aEpidemiological data on SARS-CoV-2Tang et al. \[[@bib0010]\]Genetic studyLowDescribes the evolution of the two principle strains of SARS-CoV-2Wang et al. \[[@bib0015]\]Reviewn/aDescribes the clinical characteristics of COVID-19 globallyGrant et al. \[[@bib0045]\]Reviewn/aProvides justification for the hypothesis of poorer outcomes in vitamin D deficient COVID-19 patientsLi et al. \[[@bib0050]\]Reviewn/aDescribes coronavirus mediated immune dysfunction and relates back to outcomes seen in COVID-19Huang et al. \[[@bib0055]\]Observational -- prospective cohortLowDescribes the first cohort of COVID-19 patients and their symptomatology in Wuhan, ChinaRothan et al. \[[@bib0060]\]Reviewn/aDescribes epidemiology and clinical findings of COVID-19Giamarellos-Bourboulis et al. \[[@bib0065]\]Cohort StudyLowCompares outcomes and immune response in SARS-CoV-2 infection and bacterial pneumoniaVitamin DD'Avolio et al. \[[@bib0080]\]Cohort StudyModerate -- recruitment unclear, no identification or adjustment of confounders. Baseline not describedCorrelation between SARS-CoV-2 infection and vitamin D levels.Merzon et al \[[@bib0085]\]Pre-print population studyModerate -- results not peer reviewed, but large cohort, clear design and adequate confounder adjustmentCorrelation between vitamin D levels and SARS-CoV-2 infectionMeltzer et al. \[[@bib0090]\]Preprint observational studyHigh -- results no peer-reviewed, indirect estimations of vitamin D.Correlation between vitamin D deficiency and rates of SARS-CoV-2 infection.Hastie et al. \[[@bib0095]\]Cross-sectional biobank studyLow -- Very large sample, strong statistical approachUnivariable correlation between Vitamin D and COVID-19, but relationship lost when adjusted for significant confoundersRaisi-Estabragh et al. \[[@bib0100]\]Cross-sectional biobank studyLow -- strong design, well reportedRacial disparities in COVID-19 infection rates not explained by vitamin D levelsBraiman et al. \[[@bib0105]\]Review/reportn/aDescribes epidemiological data on mortality and latitude in light of vitamin D deficiencyKara et al. \[[@bib0110]\]EpidemiologicalModerate -- Correlational data based on risk factorsDescribes vitamin D deficiency against regional rates COVID-19 mortalityDaneshkhah et al. \[[@bib0115]\]Pre-print Epidemiological modellingModerate -- indirect assessment of vitamin D deficiency, Inability to adjust for all confounding variables, results yet to be peer-reviewedModelled relationship between Vitamin D and CRP, relevant to COVID-19 cytokine stormLau et al. \[[@bib0120]\]Pre-print cross sectional studyModerate -- small sample, observational data, results yet to pass peer-reviewCorrelation between vitamin D insufficiency and COVID-19 outcomesPanagiotou et al. \[[@bib0125]\]Retrospective cohort studyModerate -- Small sample of local clinical care pathway, little adjustment for confounding factorsCorrelation between severe COVID-19 outcomes and vitamin D deficiencyRazdan et al. \[[@bib0135]\]Reviewn/aDiscusses vitamin D and the cytokine storm, in light of COVID-19Vitamin CHiedra et al. \[[@bib0165]\]Single centre observational studyModerate -- Small sample, no evaluation of confounding factorsImproved outcomes with Vitamin C administration in COVID-19 patientsWaqas Khan et al, \[[@bib0170]\]Case StudyHigh -- Singe case, adjunct treatment, subjective assessment of improvement ratePatient receiving vitamin C improved faster than deemed normalCheng \[[@bib0175]\]PerspectiveHigh -- unverified data, opinion based on little data50 COVID-19 patients had clinical improvements after vitamin C administrationZincRahman et al. \[[@bib0200]\]Reviewn/aDescribes biological hypothesis for zinc as a complementary adjunct to anti-viral therapiesFinzi \[[@bib0205]\]Case seriesHigh -- case series, small sample, subjective assessment of improvementFour patients had clinical improvement after treatment with zincBarazzoni et al. \[[@bib0215]\]Clinical guidelineModerate -- based on expert opinion in the absence of dataRecommends omega-3 supplementation in COVID-19Rogereo et al. \[[@bib0220]\]Reviewn/aDiscusses both potential benefits, but also risks of omega-3 supplementation in COVID-19SeleniumZhang et al. \[[@bib0225]\]Epidemiological studyModerate -- association study based on regional characteristicsRelationship between selenium status and COVID-19 recovery rateMagnesiumWallace \[[@bib0250]\]Reviewn/aProvides background theory on a role for magnesium in COVID-19Iotti et al. \[[@bib0255]\]Perspectiven/aSuggests a role for magnesium in COVID-19Vitamin ADe Andrade et al. \[[@bib0260]\]Reviewn/aSuggests a role for vitamin A deficiency in COVID-19

3. COVID-19 dysregulation of the immune system {#sec0015}
==============================================

On entry, SARS-CoV-2 virus binds to human alveolar epithelial cells, activating the innate and adaptive immune systems, resulting in the onset of cytokine release syndrome. This systemic cytokine barrage dysregulates host immune responses, leading to the development of acute respiratory distress syndrome (ARDS) \[[@bib0050]\]. This is particularly relevant in the vulnerable elderly, who are at greater risk of cytokine storm, and more likely to be significantly impacted by it. COVID-19 patients have a high level of interleukin (IL)-6, which is a critical inflammatory mediator involved in respiratory failure, shock and multi-organ dysfunction, and the similar SARS and MERS viruses are known to cause hyper-activation of cytotoxic T cells. Likewise, patients with severe COVID-19 symptoms and pneumonia, admitted to intensive care units, have been shown to have high levels of circulating pro-inflammatory cytokines such as IL-2, IL-7, G-CSF, and TNFα \[[@bib0055],[@bib0060]\]. This elevation of cytokines leads to hyper-inflammation and a severe hyper-cytokinemic state of inflammation. COVID-19 infection results in elevated levels of IL-6 and is associated with higher mortality. COVID-19 patients with severe symptoms have also been shown to have dysfunctional immune signaling, particularly in the human major histocompatibility complex II, particularly the HLA-DR allele, with a significant reduction in T- and B-lymphocytes and natural killer (NK) cells \[[@bib0065]\].

4. Immunomodulatory role of vitamin D {#sec0020}
=====================================

Vitamin D is a fat-soluble steroid hormone precursor that arises from ultraviolet B (UVB) radiation exposure of 7-dehydrocholesterol (7-DHC) in the epidermis of the skin, where it is transformed into the circulating precursor cholecalciferol. In the liver, cholecalciferol is hydroxylated to form 25-hydroxyvitamin D, which is transformed into the active hormone 1,25-hydroxyvitamin D (1,25(OH)~2~D) in the kidneys. Vitamin D has roles in a wide range of body systems, including in both innate and adaptive immune responses as shown in [Fig. 2](#fig0010){ref-type="fig"} . Vitamin D enhances innate cellular immunity through stimulation of expression of anti-microbial peptides, such as cathelicidin and defensins. Defensins maintain tight and gap junctions, adherens and enhance the expression of anti-oxidative genes. Viruses such as influenza are known to significantly damage the integrity of epithelial tight junctions increasing the risk of infection and pulmonary oedema. Vitamin D is known to maintain the integrity of these junctions \[[@bib0070]\]; with low levels of vitamin D receptor expression leading to increased expression of claudin-2 and inflammation. Vitamin D also promotes the differentiation of monocytes to macrophages whilst increasing superoxide production, phagocytosis and bacterial destruction. In addition, vitamin D is able to modulate the adaptive immune response, by suppressing T helper type-1 (Th1) cell function and decreasing the production of pro-inflammatory cytokines IL-2 and interferon-gamma (INF-γ). Vitamin D also promotes anti-inflammatory cytokines by Th2 cells and indirectly suppressing Th1 cells diverting pro-inflammatory cells to an anti-inflammatory phenotype as well as stimulating suppressive regulatory T cells \[[@bib0075]\].Fig. 2Immunomodulatory actions of vitamin D.IL: interleukin; TNF: Tumor necrosis factor; IFN: Interferon; Th: T-Helper; 7-DHC: 7-Dehydrocholesterol; PGE2: Prostaglandin E2.Fig. 2

Deficiency in vitamin D has been suggested to increase incidence and severity of COVID-19 infection. COVID-19 patients have been repeatedly shown to have lower levels of vitamin D, with mean plasma concentrations half that of controls \[[@bib0080]\], though the selection of the study cohort was unclear, and unadjusted relative to important confounders, leaving their conclusions unclear. Therefore, supplementation of vitamin D is suggested to boost immunity against COVID-19 and reduce human mortality; however this hypothesis needs to be tested in human trials. It has also been suggested that adequate vitamin D levels may help to protect the respiratory epithelium from pathogenic invasion, decreasing risk of infection. A pre-print population study in Israel also found that vitamin D correlated with disease incidence, even after adjustment for sociodemographic and comorbidity variables \[[@bib0085]\]. This finding is also supported in an additional pre-print study, currently under review \[[@bib0090]\], however these results must be corroborated. However, large biobank studies concluded that vitamin D deficiency was not related to incidence of COVID-19, nor did it explain differences in demographic variation of infection rates \[[@bib0095],[@bib0100]\]. It appears that associations with vitamin D and COVID-19 rely heavily on univariate analysis and do not remain consistent after adjustment for important confounding variables, such as comorbidity and sociodemographic factors. While it is unclear whether vitamin D status affects infection rates, there is evidence to suggest a role in mitigating disease severity. The mortality rates related to COVID-19 vary from country to country, and in the southern hemisphere the mortality rates are lower than in the northern hemisphere \[[@bib0105]\]. One hypothesis explaining this pattern is that people in the northern hemisphere classically have more prevalent vitamin D deficiency, due to lack of sun exposure in winter as compared to summer period in the southern hemisphere during peak pandemic months (January-May) \[[@bib0105]\]. It has also been shown that countries with higher prevalence of vitamin D deficiency tend to have a higher burden of COVID-19 morbidity and mortality \[[@bib0110]\]. Spain and Italy have high prevalence of vitamin D deficiency, which is linked with other important health factors including, hypertension, diabetes, obesity and ethnicity, which appear to be associated with an increased risk of severe COVID‐19 infection. Evidence has shown directly that mortality rate is higher in COVID-19 patients with vitamin D deficiency and the mortality rate is lower in Nordic countries (Norway, Sweden, Iceland, Finland, Greenland and Denmark) \[[@bib0105]\] possibly because of the rarity of vitamin D deficiency due to widespread supplement use. In addition, C-reactive protein (CRP), a marker of inflammation and surrogate marker for cytokine storm, was highly expressed in patients with severe COVID-19 symptoms and correlated with vitamin D deficiency \[[@bib0115]\]. Likewise, a pre-print retrospective study of twenty COVID-19 patients, showed a link between vitamin D insufficiency and severe COVID-19. The participants with vitamin D inefficiency were more likely to have coagulopathy and suppressed immune function \[[@bib0120]\]. in another study patients with deficiency were more likely to require intensive care admission in 134 inpatients \[[@bib0125]\] While mechanistic understanding of the role of vitamin D in COVID-19 is lacking, genetic studies of the SARS-CoV-2 virus have identified a number of protein targets likely regulated by it, however no definitive evidence has been found. However, with the evidence currently available, many agencies are beginning to review whether supplementation should be broadly recommended.

4.1. Vitamin D deficiency and COVID-19 associated risk factors {#sec0025}
--------------------------------------------------------------

Vitamin D is strongly linked to a range of COVID-19 risk factors. Vitamin D insufficiency is linked with advanced age, obesity, male sex, hypertension, concentration in northern climates, and coagulopathy, all of which are associated with poorer outcomes. With increased age, concentrations of active vitamin D decrease due to less sunlight exposure and reduced production of 7-DHC in the skin. This may also partly explain why the mortality rate of COVID-19 is higher in older adults. There is also a well-documented shift in the immune system towards a pro-inflammatory state in older adults (known as 'inflamm-aging') which leads to chronic low-grade inflammation, a steady accumulation of biological injury, and eventually progression of chronic disease \[[@bib0130]\]. It has been shown that vitamin D is associated with increased anti-inflammatory and decreased pro-inflammatory cytokines in older adults. The positive influence of vitamin D on the immune system is helpful during cytokine storm, relevant to COVID-19 patients with ARDS \[[@bib0135]\]. In a systematic review and meta-analysis of eight observational studies involving 20,966 subjects it was noted that those with low levels of vitamin D had an increased risk of pneumonia \[[@bib0140]\].

4.2. Protective role of vitamin D in viral infection {#sec0030}
----------------------------------------------------

Vitamin D supplements are known to aid in reducing the incidence and severity of viral infection and there is an inverse relationship between upper respiratory tract infection and serum 25-hydroxyvitamin D levels. While the effect of vitamin D against SARS‐CoV‐2 infection has not yet been shown, supplementation could potentially reduce pro-inflammatory cytokines and subsequently limit acute respiratory distress syndrome associated mortality in COVID-19 patients. A number of human clinical trials have been registered to determine the effect of vitamin D supplementation in COVID-19 patients ([Table 2](#tbl0010){ref-type="table"} ).Table 2Registered trials of vitamin D in patients with COVID-19.Table 2Trial NumberStudy designInterventionParticipantsPrimary outcomesCountryNCT04334005Randomized, Parallel, Double blindedOne dose of 25,000 IU of vitamin D200 non-severely symptomatic patientsNumber of deaths of any causeSpainNCT04344041Randomized,, Parallel, Open LabelOne oral dose of 400,000 or 500,000 IU vitamin D.260 subjects ≥ 70 years old with COVID-19Number of deaths of any cause within 14 daysFranceNCT04335084Randomized, Double-Blind, Placebo-Controlled Phase 2aVit D, C, Zinc and drug hydroxychloroquine600 subjects ≥18 years at high riskPrevention of COVID-19 symptomsUSANCT04385940Phase 3 RCT50,000 IU Vitamin D64 patients with COVID19Biochemical and clinical outcomesUSANCT04449718Interventional trial200,000IU vitamin D200 COVID-19 PatientsLength of hospitalizationBrazilNCT04483635Phase 3 placebo controlled RCT100,000IU followed by 16 weeks of a 1000IU supplementation2414 Healthy patients working in high-risk locations for SARS-CoV-2 infectionIncidence of new COVID-19 infectionCanadaNCT04482673Interventional Phase 46000IU daily, with or without a 20000IU bolus dose140 participants with or without COVID-19SARS-CoV-2 Ab titres, serum vitamin DUSANCT04407286Phase 1 interventional RCT10000−15,000IU Vit D/day for 2−5 weeks until \>50 nm/mL100 COVID-19 patientsSymptom severityUSANCT04411446Phase 4 interventional RCT500,000 IU dose vitamin D1265 patients with COVID-19Symptom severityArgentinaNCT04459247Interventional RCT60,000 IU dose of vitamin D30 participants with COVID-19Inflammation and COVID-19 statusIndiaNCT04363840Phase 2 RCTWeekly 50,000IU vitamin D for 2 weeks plus 81 mg of aspirin1080 Patients with COVID-19 diagnosisHospitalization rateUSANCT04351490Interventional RCT2000IU vit D daily for 2 months3140 COVID-19 patients over 60Survival rateFranceNCT04344041Phase 3 interventional RCT200,000 or 50,000IU vitamin D260 COVID-19 patients over 70All cause and COVID-19 mortality, symptom severityFranceNCT04334512Phase 2 interventional studyUnspecified dose of vitamin D, alongside hydroxychloroquine, azithomyosin, vitamin C and zinc600 COVID-19 patientsRecovery rate, symptom severityUSANCT04476680Interventional RCT1000IU vitamin D daily4400 healthy volunteersRate of COVID-19 infectionUKNCT04386850Phase 2/3 interventional RCT25mcg Vitamin D daily1500 participants -- COVID-19 positive, alongside negative testing healthcare workers and family members of COVID-19 patientsRate of infection\
Severity of disease\
Hospitalization\
Duration of disease\
Mortality\
VentilationIran

5. Immunomodulatory role of vitamin C {#sec0035}
=====================================

Vitamin C, or ascorbic acid, is a water-soluble nutrient that cannot be synthesized by humans. Vitamin C acts as an anti-oxidant that can scavenge reactive oxygen species (ROS), thereby, protecting biomolecules such as proteins, lipids and nucleotides from oxidative damage and dysfunction. Vitamin C accumulates in leukocytes, in concentrations of 50−100-fold higher than in the plasma. During infection, vitamin C that is present in leukocytes is rapidly utilized. Disturbance of the balance between antioxidant defenses and oxidant generation can alter multiple signaling pathways involving pro-inflammatory transcription factors, such as nuclear factor кB (NF-кB). Increasing levels of oxidants lead to activation of NF-кB, triggering a signaling cascade, with the end result of further production of oxidative species and inflammatory mediators. NF-кB is involved in inflammatory responses, the pathogenesis of certain diseases and viral infection. Inhibition of NF-кB can be a therapeutic mode against viral infections \[[@bib0145]\].

Vitamin C is well known to confer a protective benefit in infectious disease. Indeed, supplementation is known to support respiratory defense mechanisms, preventing viral infections, and reducing their duration and severity as well as having anti-histamine properties that can improve flu-like symptoms. Interestingly, patients with acute respiratory infections such as, pneumonia or tuberculosis have decreased plasma vitamin C concentrations and, vitamin C administration reduces the severity and duration of pneumonia in elderly patients \[[@bib0150]\]. This key protective action against respiratory infection makes it a target of interest in COVID-19 (Fig.3).

5.1. Vitamin C and immune responses in COVID-19 {#sec0040}
-----------------------------------------------

Cytokine storm during COVID-19 infection escalates as disease progresses, and vitamin C has been suggested as a counter to this. For instance, the pro-inflammatory cytokines, IL-1β and TNF-α increase rapidly after infection, and the acute response triggered by this stimulates further secretion of IL-6 and IL-8 promoting an ongoing pro-inflammatory state. TNF-α is currently under investigation in facilitating entry of SARS-CoV-2 into host cells \[[@bib0155]\]. Vitamin C is known to reduce the levels of pro-inflammatory cytokines including TNF-α and increase anti-inflammatory cytokines (IL-10). Clinical studies have demonstrated that intake of 1 g/day of vitamin C increases IL-10 secretion by peripheral blood mononuclear cells. IL-10 works as a negative feedback mechanism with IL-6 and controls inflammation, critical in COVID-19. Older people are more susceptible to infection because of low immune cell function and immuno-senescence \[[@bib0160]\]. Data shows that COVID-19 patients are at a higher risk of pneumonia. in another small trial improvements in inflammatory biomarkers and some respiratory parameters were noted following intravenous administration of vitamin C \[[@bib0165]\]. A case study of a patient treated with high-dose vitamin C after development of ARDS was able to be removed from ventilation after 5 days which was deemed unusually early, however it should be noted that she also received anti-viral medications \[[@bib0170]\]. Vitamin C has also been shown to have a role in sepsis secondary to pneumonia, also seen in COVID-19. There is unpublished data suggesting beneficial effects of high dose vitamin C supplementation in 50 Chinese patients with severe symptoms, though this requires substantiation \[[@bib0175]\]. Therefore, vitamin C supplementation is a sensible option in micronutrient deficient individuals that are at risk of COVID-19 infection to assist with the prevention and support of immune responses. To this end, several clinical trials are evaluating Vitamin C supplementation in COVID-19 patients ([Table 3](#tbl0015){ref-type="table"} ).Table 3Registered clinical trials of vitamin C in patients with COVID-19.Table 3Trial NumberStudy designInterventionEligibility criteriaPrimary outcomesCountryNCT04264533Randomized, triple blinded, parallel design. Phase 224 g/day vitamin C for 7 daysCOVID 19 in ICU patients, ≥ 18 years old. Diagnosed as serious or critical SARIVentilation free daysChinaNCT04323514Uncontrolled longitudinal, open-label, single-group study10 g intravenous vitamin C in addition to conventional therapy500 participants of all ages with the indication of incubation, positive COVID 19 and interstitial pneumoniaIn-hospital mortalityItalyNCT03680274Randomized, quadruple blinded, phase 3, parallel study200 mg/kg/day and 16 doses of vitamin C intravenously800 patients ≥ 18 years old; with COVID-19 in ICU. Treated with a continuous intravenous infusion of vasopressorsDecreased death rate and dependency on mechanical ventilationCanadaNCT04395768Phase 2 interventional study50 mg/kg vitamin C every 6 h day 1, 100 mg/kg/6 h for next 7 days200 patients with a COVID-19 diagnosisSymptom severity, length of hospital stay, ventilation requirementAustralia[^1]

6. Immunomodulatory role of zinc {#sec0045}
================================

Zinc is a key trace mineral, involved in many biological processes including immunity and it is vital in both the innate and acquired responses to viral infection. Zinc deficiency significantly increases pro-inflammatory cytokines and remodeling of lung tissue is noted, an effect which was partially countered by zinc supplements \[[@bib0180]\]. Furthermore, zinc deficiency results in an alteration of cell barrier function in lung epithelial tissues, via up-regulation of IFN-γ, TNF-α and Fas receptor signaling as well as apoptosis *in vitro*. Zinc is purported to be a vital mineral during COVID-19 infection because of its dual immunomodulatory and anti-viral properties \[[@bib0185],[@bib0190]\].

6.1. Immunomodulatory and anti-viral properties of zinc {#sec0050}
-------------------------------------------------------

Zinc plays a significant role in the recruitment of neutrophil granulocytes and chemotactic activity and has positive effects on NK cells, phagocytosis, generation of oxidative burst, and CD4+ and CD8 + T cells. Zinc deficiency reduces lymphocyte counts and impairs their function; in fact, zinc supplementation increases the number of T cells and NK cells and increases IL-2 and soluble IL-2 receptor expression. Zinc has been shown to inhibit the synthesis, replication and transcription complex of coronaviruses \[[@bib0195]\]. It can also interfere directly with viral replication and protein synthesis, providing beneficial and therapeutic effects against viral infections \[[@bib0185]\].

6.2. Zinc and COVID-19 {#sec0055}
----------------------

Due to the immunomodulatory and anti-viral properties of zinc, it has the potential to be a supportive treatment in COVID-19 patients ([Fig. 3](#fig0015){ref-type="fig"} ). It has been suggested that zinc supplementation may increase the efficacy of other treatments currently under investigation such as hydroxychloroquine \[[@bib0200]\]. A case series of four COVID-19 patients treated with high-dose zinc also showed both clinical symptomatic improvements \[[@bib0205]\]. Studies have shown that zinc supplementation is able to decrease COVID-19 related symptoms such as lower respiratory tract infection. These effects have been suggested to be due to inhibition of viral uncoating, binding and replication, and may be relevant to COVID-19. A clinical trial registered in Australia will determine the use of intravenous zinc administration COVID-19 positive individuals \[[@bib0210]\].Fig. 3COVID19 protective actions of vitamin C, E zinc, selenium and omega-3 fatty acids. IL: interleukin; NK: Natural Killer; BFGF2: Basic Fibroblast Growth Factor 2; TNF: Tumor necrosis factor; IFN: Interferon.Fig. 3

7. Immunomodulatory role of omega-3 fatty acids {#sec0060}
===============================================

Omega-3 fatty acids are polyunsaturated fatty acids and include eicosapentaenoic and docosahexaenoic fatty acids, and are well known to have favorable effects on immunity and inflammation. Of interest, omega-3 fatty acids exert anti-viral effects by inhibiting influenza virus replication. According to the European Society for Parenteral and Enteral Nutrition expert statement, the use of omega-3 fatty acids may improve oxygenation in COVID-19 patients, although firm evidence is still missing \[[@bib0215]\]. Others however have suggested caution in the use of the omega-3 s in COVID-19 patients, citing evidence showing a counter-intuitive increase in oxidative stress and inflammation due to increased susceptibility of cellular membranes to damage \[[@bib0220]\]. Until there is validated trial data, supplementation, particularly in high doses, must be performed with care in this population.

8. Immunomodulatory role of other nutrients {#sec0065}
===========================================

The anti-oxidant Vitamin E, and trace element selenium, are major components of anti-oxidant defense. Epidemiological studies demonstrate that deficiencies in either of these nutrients alters immune responses and viral pathogenicity. It has been noted, that there is a correlation between geographic selenium levels and COVID-19 cure rates in different Chinese provinces \[[@bib0225]\]. Vitamin E and selenium both act through anti-oxidant pathways to increase the number of T cells, enhance mitogenic lymphocyte responses, increase IL-2 cytokine secretion, enhances NK cell activity, and, decreases the risk of infection (Fig. 3). Selenium and vitamin E supplementation has also been shown to increase resistance to respiratory infections \[[@bib0230],[@bib0235]\]. It is worthy to note that mixed tocopherols are more effective than α-tocopherol alone, due to the range of receptors for these nutrients \[[@bib0240]\].Despite these beneficial roles in immunity, there is limited information on the effects of vitamin E or selenium supplementation in humans with COVID-19 infection, though patients are encouraged to have adequate intakes of these antioxidant nutrients.

Other nutrients have been proposed to have a potential role in the management of COVID-19, including magnesium and vitamin A. While the mechanisms are still unclear, magnesium deficiency has been shown to have a range of effects on the immune system. Magnesium deficiency is associated with decreased immune cell activity and increased inflammation, including of IL-6, central to the pathology of the cytokine storm associated with COVID-19 \[[@bib0025]\]. Magnesium is also known to have a relationship to vitamin D physiology, as it has been shown to regulate the levels of the hormone in vivo \[[@bib0245]\]. This may suggest magnesium as playing some role in the beneficial relationship between vitamin D and COVID-19 outcomes. These relationships have led a number of authors and commentators to suggest that magnesium might be used to combat the symptoms of COVID-19, however concrete data of efficacy in prevention, or treatment is currently lacking \[[@bib0250],[@bib0255]\]. Similarly, vitamin A is known to have beneficial roles in respiratory infections, again leading to speculation about a potential protective role in COVID-19 \[[@bib0260]\]. While these nutrients are likely to have value in general health both in and out of the SARS-CoV-2 setting, there is no experimental data to support a specific role in the disease.

9. The role of nutritional supplementation in COVID-19 {#sec0070}
======================================================

Adequate levels of vitamins C, D and E are crucial during COVID-19 to reduce symptom burden and lessen the duration of respiratory infection. Research also supports a role for minerals such as zinc as they have antiviral effects and may improve immune responses and suppress viral replication. Therefore, the consumption of adequate amounts of vitamins and minerals through diet is essential to ensure the proper functioning of the immune system. Fruits, vegetables, meat, fish, poultry and dairy products are good source of these vitamins and minerals ([Table 4](#tbl0020){ref-type="table"} ). To support immune function during COVID-19 disease higher dietary intakes of vitamins D, C and E, zinc and omega-3 fatty acids could be beneficial \[[@bib0025]\]. It is worth noting however, that much of the evidence surrounding the use of these nutrients in COVID-19 patients, utilize doses too high to come solely from diet. Supplementation with higher doses of these nutrients during COVID-19 infection, have shown positive outcomes, and given their low risk profile are a sensible addition to patient care. However, further research needs to be undertaken to define the effective dosage of vitamins C, D, E, zinc and omega-3 fatty acids to protect individuals or alleviate symptoms against COVID-19.Table 4Sources and daily requirement of vitamins D, C, E, zinc, omega-3 fatty acids.Table 4NutrientsPlant sourcesAnimal SourcesRDI/dayEffective dosage/day**Vitamin D**\
![](fx1_lrg.gif)Wild mushroom, fortified orange juice, fungiMilk, eggs, margarine, fortified cheese, yogurt, bread5−15 μg20−50 μg \[[@bib0275]\]**Vitamin C**\
![](fx2_lrg.gif)Citrus fruits (i.e. orange, grapefruit, lime, mandarin), strawberries, kiwi, pineapple, tomato, broccoli, cabbage, kale, spinachChicken, beef liver, oysters, milk40−85mg6000−8000 mg/day \[[@bib0280]\]**Zinc**\
Zn^2+^Beans, nuts, whole grains, fortified breakfast cerealsPoultry, red meat, crab, Oysters, lobster, dairy products8−14 mg30−50 mg \[[@bib0285]\]**Vitamin E**\
![](fx3_lrg.gif)Nuts (hazelnut, almonds, peanuts), seeds, vegetable oils, green leafy vegetables, mango, avocado, fortified cerealsSalmon, trout, crayfish, lobster7−10mg50−200 mg \[[@bib0290]\]**Selenium**\
Se^2−^Nuts, whole grains, cereals, mushroomsDairy products Poultry, red meat, seafood60−70 μgYet to be determined**Omega-3 fatty acids**\
![](fx4_lrg.gif)Flaxseed, chia seed, walnutsEggs, fish (salmon, sardine, mackerel), lobster90−160mg1000−3000 mg \[[@bib0295]\][^2]

10. Conclusion and future prospects {#sec0075}
===================================

The effects of vitamins C, D, E, zinc, selenium and omega-3 fatty acids on the immune system and the possible benefits to those suffering from COVID-19 are presented. These are particularly pertinent in the vulnerable elderly population, who represent a disproportionate burden of morbidity and mortality in these times. All of the nutrients mentioned have a feasible role in the support of COVID-19 patients. Supplementation of higher dosage of vitamins D, C and zinc may have a positive effect during COVID-19 infection. However, clinical trials based on the associations of diet and COVID-19 are lacking. Some clinical studies have been registered and are currently being conducted to determine the effectiveness of certain nutrients in patients with COVID-19. Hopefully, the results of these trials will clarify the use of micronutrients during SARS-CoV-2 infection. It is also important to investigate other important immunomodulatory micronutrients such as vitamin B in COVID-19, to further explore the role of nutrition in disease outcomes \[[@bib0265],[@bib0270]\]. On balance, given the negligible risk profile of supervised nutritional supplementation, weighed against the known and possible benefits, it appears pertinent to ensure adequate, if not elevated intake of these key vitamins and minerals in people both at risk of, and suffering from COVID-19.
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[^1]: COVID-19, coronavirus disease-19; ICU, intensive care unit; SARI, Severe Acute Respiratory Infection.

[^2]: AI, adequate intake; Effective dosage, effective dose of supplements during infection and respiratory diseases; RDA, recommended dietary intake, based on Australia and New Zealand recommendations \[[@bib0300]\].
